

35

 참고 문헌

1. 대한외과학회. 외과학. 제1판. 서울: 군자출판사; 2010; 885.
2. 박해린. 유방수술의 도해. 서울: 가본의학; 2005; 24-7.
3. 중앙암등록본부. 2009년 암등록통계 보도자료. http://ncc.re.kr/manage/manage03_033_view.jsp?bbsnum=209&hSelSearch=&hTxtKeyword=¤t_page=1&cd=null
4. 한국유방암학회. 유방학. 제2판. 서울: 일조각; 2005; 1-2.
5. Ambrogetti D, Berni D, Catarzi S, Ciatto S. The role of ductal galactography in the differential diagnosis of breast carcinoma. *Radiol Med (Torino)* 1996;91:198-201.
6. Ambrogetti D, Berni D, Catarzi S, S. C. The role of ductal galactography in the differential diagnosis of breast carcinoma. *Radiol Med* 1996;91:198-201.
7. Ames V, Britton PD. Stereotactically guided breast biopsy: a review. *Insights Imaging* 2011;2:171-6.
8. Andersen JA, Gram JB. Radial scars of benign and malignant breast: comparative features and significance. *J Pathol* 1985;147:23-32.
9. Anderson TJ, Ferguson DJ, Raab GM. Cell turnover in the "resting" human breast: influence of parity, contraceptive pill, age and laterality. *Br J Cancer* 1982;46:376-82.
10. Anson BJ, Wright RR, Wolfer JA. Blood supply of the mammary gland. *Surg Gynecol Obstet* 1939;69:468-73.
11. Appiani F, Carroll BT, Munoz C, Trecco J. Tamoxifen-SSRIs interaction: clinical manifestations of inhibition and lack of inhibition of CYP2D6. *Ann Clin Psychiatry* 2011;23:152-3.
12. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. *Lancet* 2002;359:2131-9.
13. Beatson G. on the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. *George Thomas Beatson* 1896;148:104-7.
14. Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Böhm-Vélez M, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. *JAMA* 2008;299:2151-63.
15. Berg WA, Campassi CI, OB. I. Cystic lesions of the breast: sonographic-pathologic correlation. *Radiology* 2003;227:183-91.
16. Berg WA. Image-guided breast biopsy and management of high-risk lesions. *Radiol Clin North Am* 2004;42:935-46.
17. Biglia N, Cozzarella M, Cacciari F, Ponzone R, Roagna R, Maggiorotto F, et al. Menopause after breast cancer: a survey on breast cancer survivors. *Maturitas* 2003;45:29-38.
18. Bissett D DJ, George WD. Gynaecological monitoring during tamoxifen therapy. *Lancet* 1994;344:1244.
19. Blamey RW. Guidelines on endocrine therapy of breast cancer EUSOMA. *Eur J Cancer* 2002;38:615-34.
20. Blatt MH, Wiesbader H, Kupperman HS. Vitamin E and climacteric syndrome: failure of effective control as measured by menopausal index. *AMA Arch Intern Med* 1953;91:792-9.
21. Blommers J, de Lange-De Klerk ES, Kuik DJ, Bezemer PD, Meijer S. Evening primrose oil and fish oil for severe chronic mastalgia: a randomized, double-blind, controlled trial. *Am J Obstet Gynecol* 2002;187:1389-94.
22. Brenin D. Management of the palpable breast mass. In: Harris JR, Lippman ME, Morrow M, et al. *Disease of the breast*. 3rd ed. Lippincott Williams & Wilkins 2004; 33-45.
23. Brennan M, Houssami N, J. F. Management of benign breast conditions. Part 3--Other breast problems. *Aust Fam Physician* 2005;34:353-5.
24. Brenner RJ, Jackman RJ, Parker SH, Evans WP 3rd, Philpotts L, Deutch BM, et al. Percutaneous core needle biopsy of radial scars of the breast: when is excision necessary? *AJR Am J*

- Roentgenol. 2002;179:1179-84.
25. Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. *J Clin Oncol* 2007 Sep 1;25:3797-9.
 26. Campagnoli C AC, Ambroggio S, Lotano MR, Peris C. Differential effects of various progestogens on metabolic risk factors for breast cancer. *Gynecol Endocrinol* 2007;S1:22-31.
 27. Carpenter JS, Andrykowski MA, Cordova M, Cunningham L, Studts J, McGrath P, et al. Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. *Cancer* 1998;82:1682-91.
 28. Cheung KL, Alagaratnam TT. A review of nipple discharge in Chinese women. *J R Coll Surg Edinb* 1997;42:179-81.
 29. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. *Cochrane Database Syst Rev* 2009; CD007245.
 30. Cho N, Moon WK, Cha JH, Kim SM, Kim SJ, Lee SH, et al. Sonographically guided core biopsy of the breast: comparison of 14-gauge automated gun and 11-gauge directional vacuum-assisted biopsy methods. *Korean J Radiol* 2005;6:102-9.
 31. Clemente CD. *Gray's Anatomy*, 13th, LEA & Febiger, Philadelphia; 1985, p.486.
 32. Cobleigh MA BR, Bush T. Estrogen replacement therapy in breast cancer survivors. A time for change. *Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA* 1994;272:540-5.
 33. Cohen I, Figer A, Tepper R, Shapira J, Altaras MM, Yigael D, et al. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. *Gynecol Oncol* 1999;72:202-7.
 34. Cohen I, Potlog-Nahari C, Shapira J, Yigael D, Tepper R. Simple ovarian cysts in postmenopausal patients with breast carcinoma treated with tamoxifen: long-term follow up. *Radiology* 2003;227:844-8.
 35. Colditz GA, Kaphingst KA, Hankinson SE, Rosner B. Family history and risk of breast cancer: nurses' health study. *Breast Cancer Res Treat* 2012;133(3):1097-104.
 36. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, De-lozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. *N Engl J Med* 2004;350:1081-92.
 37. Creasman W. Weighing HRT use after breast cancer. *OBG management* 2002: 25-32.
 38. Croshaw RL, Erb KM, Shapiro-Wright HM, Julian TB. The need for axillary dissection in patients with positive axillary sentinel lymph nodes. *Curr Oncol Rep* 2011;13:5-10.
 39. Crystal P, Koretz M, Shcharynsky S, Makarov V, Strano S. Accuracy of sonographically guided 14-gauge core-needle biopsy: results of 715 consecutive breast biopsies with at least two-year follow-up of benign lesions. *J Clin Ultrasound* 2005;33:47-52.
 40. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. *JAMA* 1999;281:2189-97.
 41. Cunningham F, Leveno K, Bloom S, Hauth J, Gilstrap L, Wenstrom K, In: F. Gray Cunningham, editor. *Williams Obstetrics*, 22nd ed. New York: Mc Graw Hill; 2005. p.699-700.
 42. Cunningham F, Kenneth L, Bloom S, Hauth J, Gilstrap L, Wenstrom K. *Williams Obstetrics*. Rouse D, Rainey B, Spong C, WendellIn GD, editors. 22ed. New York: McGraw-Hill; 2005. p. 700.
 43. Cuzick Jea. SABCS: Adjuvant Therapy for DCIS Reduces the Risk of Recurrence. *SABCS* 2009; 34.
 44. D'Orsi CJ, Bassett LW, Berg WA, Feig SA, Jackson VP, Kopan DB, et al. *Breast Imaging Reporting and Data System, BI-RADS: Mammography*, 4th edition. Reston: American College of Radiology; 2003
 45. Dent DM, Hacking EA, Wilkie W. Benign breast disease: clinical classification and disease distribution. *Br J Clin Pract* 1988;42:Suppl:69-71.
 46. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. *Climacteric* 2003;6:15-52.
 47. Dixon JM. Conserviative management of fibroadenoma of the breast. *Br J Surg* 1996;83:1798-9.
 48. Dupont WB, Page DL. Risk factors for breast cancer in women with proliferative breast disease. *N Engl J Med* 1985;312:146-51.
 49. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005;365:1687-717.
 50. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. *JAMA* 2005;293:1245-56.
 51. Erlandson RA, Rosen PP. Infiltrating myoepithelioma of the breast. *Am J SurgPathol* 1982;6:785-93.
 52. Ernster VL, Goodson WH 3rd, Hunt TK, Petrakis NL, Sickles EA, R. M. Mastalgia. *Surgery* 1985;97:490-4.
 53. Falkenberry SS. Nipple discharge. *Obstet Gynecol Clin North Am* 2002;29:21-9.

54. Farina MA, Newby BG, Alani HM. Innervation of the nipple-areola complex. *Plast Reconstr Surg*. 1980;66:497-501.
55. Fentiman IS, Caleffi M, Brame K, Chaudary MA, Hayward JL. Double-blind controlled trial of tamoxifen therapy for mastalgia. *Lancet* 1986;1:287-8.
56. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. *N Engl J Med* 1995;333:1456-61.
57. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst* 2005 Nov 16;97:1652-62.
58. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. *J Clin Oncol* 1998;16:441-52.
59. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. *Lancet* 1999;353:1993-2000.
60. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. *N Engl J Med* 2002;347:567-75.
61. Fisher ER, Palekar AS, Kotwal N, Lipana N, Palekar AS, Kotwal N, et al. A nonencapsulated sclerosing lesion of the breast. *Am J Clin Pathol* 1979;71:240-6.
62. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. *J Natl Cancer Inst* 1994;86:527-37.
63. Flobbe K, Bosch AM, Kessels AG, Beats GL, Nelemans PJ, von Meyenfeldt MF, et al. The additional diagnostic value of ultrasonography in the diagnosis of breast cancer. *Arch Intern Med* 2003;163:1194-9.
64. Friedlander LC, Roth SO, Gavenonis SC. Results of MR imaging screening for breast cancer in high-risk patients with lobular carcinoma in situ. *Radiology* 2011;261:421-7.
65. Gateley CA, Miers M, Mansel RE, LE, H. Drug treatments for mastalgia: 17 years experience in the Cardiff Mastalgia Clinic. *J R Soc Med* 1992;85:12-7.
66. Gilleard O, Goodman A, Cooper M, Davies M, Dunn J. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. *World J Surg Oncol* 2008;6:61.
67. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. *JAMA* 2011;305:569-75.
68. Goehring C, Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. *Epidemiol Rev* 1997;19:310-27.
69. Goodwin PJ, DeBoer G, Clark RM, Catton P, Redwood S, Hood N, et al. Cyclical mastopathy and premenopausal breast cancer risk. Results of a case-control study. *Breast Cancer Res Treat* 1995;33:63-73.
70. Gordon PB, Goldenberg SL, Chan NH. Solid breast lesions: diagnosis with US-guided fine-needle aspiration biopsy. *Radiology* 1993;189:573-80.
71. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. *N Engl J Med* 2003;349:1793-802.
72. Goyal A, Mansel RE, Efamast Study Group. A randomized multicenter study of gamolenic acid (Efamast) with or without antioxidants, vitamins and minerals in the management of mastalgia. *Breast J* 2005;11:41-7.
73. Gülay H, Bora S, Kılıç turgay S, Hamaloğlu E, HA. G. Management of nipple discharge. Gulay H, Bora S, Kiliturgay S, Hamaloglu E, Goksel HA 1994;178:471-4.
74. Guttuso T Jr, Kurlan R, McDermott MP, Kiebertz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. *Obstet Gynecol* 2003;101:337-45.
75. Halsted W. The results of operations for the care of cancer of the breast performed at the Johns Hopkins Hospital from June 1889 to January 1894. *Ann Surg* 1894;20:497.
76. Hammond MG, Hatley L, Talbert LM. A double blind study to evaluate the effect of methyl dopa on menopausal vasomotor flushes. *J Clin Endocrinol Metab* 1984;58:1158-60.
77. Hann L, Ducatman BS, Wang HH, Fein V, McIntire JM. Nonpalpable breast lesions: evaluation by means of fine-needle aspiration cytology. *Radiology* 1989;171:373-76.
78. Hertel BF, Zaloudek C, Kempson RL. Breast adenomas. *Cancer* 1976;37:2891-905.
79. Holmberg L, H A. HABITS steering and data monitoring committees: HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial

- stopped. *Lancet* 2004;363:453-5.
80. Houssami N, Cheung MN, Dixon JM. Fibroadenoma of the breast. *Med J Aust* 2001;174:185-88.
 81. Hughes LE, Mansel RE, Webster DJ. Aberrations of normal development and involution (ANDI): a new perspective on pathogenesis and nomenclature of benign breast disorders. *Lancet* 1987;2:1316-9.
 82. Hussain AN, Policarpio C, MT. V. Evaluating nipple discharge. *Obstet Gynecol Surv* 2006;61:278-83.
 83. [Internet]. Wikipedia. Wikimedia Foundation, Inc; [cited-2011Sep25]. Available from: <http://en.wikipedia.org/>.
 84. Ikeda DM. *Breast Imaging: the Requisites*. Philadelphia: Elsevier Mosby; 2011; 239-90.
 85. Inal MM, Incebiyik A, Sancı M, Yildirim Y, Polat M, Pilancı B, et al. Ovarian cysts in tamoxifen-treated women with breast cancer. *Europ J Obstet Gynecol* 2005;120:104-6.
 86. Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, et al. Invasive lobular breast cancer: subtypes and outcome. *Breast Cancer Res Treat* 2012;133(2):713-23.
 87. Jackson VP. The status of mammographically guided fine needle aspiration biopsy of nonpalpable breast lesions. *Radiol Clin North Am* 1992;30:155-66.
 88. Jacobs TW, Byrne C, Colditz G, Connoiy JL, schnitts. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. *N Engl J Med* 1999;340:430-6.
 89. James K, Bridger J, Anthony PP. Breast tumour of pregnancy ('lactating' adenoma). *J Pathol* 1988;156:37-44.
 90. Jang M, Cho N, Moon WK, Park JS, Seong MH, Park IA. Underestimation of atypical ductal hyperplasia at sonographically guided core biopsy of the breast. *AJR Am J Roentgenol* 2008;191:1347-51.
 91. Jansen RA, Page DL, Dupont WD, Rogners LW. Invasive breast cancer risk in women with sclerosing adenosis. *Cancer* 1989;64:1977-83.
 92. Jaspars JJP, Posma AN, van Immerseel AA, Gittenberg-de-Groot AC. The cutaneous innervation of the female breast and nipple-areola complex: implications for surgery. *Br J Plast Surg* 1997;50:249-59.
 93. Johnson L, Pinder S, Douek M. Multiple foci of invasive breast cancer: can breast MRI influence surgical management? *Breast Cancer Res Treat* 2011;128:1-5.
 94. Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. *Br J Pharmacol* 2006;147(S1):269-76.
 95. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. *J Clin Oncol* 2001;19:343-53.
 96. Ko E, Han W, Lee JW, Cho J, Kim EK, Jung SY, et al. Scoring system for predicting malignancy in patients diagnosed with atypical ductal hyperplasia at ultrasound-guided core needle biopsy. *Breast Cancer Res Treat* 2008;112:189-95.
 97. Kopans DB. *Breast Imaging*, 2nd ed. New York: Lippincott-Raven; 199.
 98. Kuerer H. *Breast surgical oncology*. In: Kuere editors, Texas: Mc Graw Hill; 2010. p.345-1.
 99. Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA* 2006;295:2742-51.
 100. Lee JW, Han W, Ko E, Cho J, Kim EK, Jung SY, et al. Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focus. *J Surg Oncol* 2008;98:15-20.
 101. Leitch AM, Dodd GD, Costanza M, Linver M, Pressman P, McGinnis L, et al. American Cancer Society guidelines for the early detection of breast cancer: update 1997. *Cancer J Clin* 1997;47:150-3.
 102. Lewis D, WF. R. A study of results - Johns Hopkins Hospital, 1889±1931. *Ann Surg* 1932;25:336-400.
 103. Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. *Am J Surg Pathol* 1986;10:382-93.
 104. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM Jr, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. *J Clin Oncol* 1997;15:969-73.
 105. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. *Lancet* 2000;356:2059-63.
 106. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. *J Clin Oncol* 2002;20:1578-83.
 107. Lubian Lopez DM, Fernandez YG, Rodriguez BR, Lopez FM, Delgado RC. Value of the progesterone test in screening for endometrial pathology in asymptomatic postmenopausal women receiving treatment with tamoxifen. *Menopause* 2010;17:487-93.
 108. Lumachi F, Ermani M, Brandes AA, Boccagni P, Basso SM, fau à le G. Breast complaints and risk of breast cancer: popu-

- lation-based study of 2,879 self-selected women and long-term follow-up. *Biomed Pharmacother* 2002;56:88-92.
109. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. *J Clin Oncol* 2005;23:7703-20.
 110. Machado F, Rodrigues JR, Leon JP, Rodrigues JR, Parrilla JJ, Abad L. Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. *Eur U Gynaecol Oncol* 2005;26:257-65.
 111. Mackey JR, Joy AA. Skeletal health in postmenopausal survivors of early breast cancer. *Int J Cancer* 2005;114:1010-5.
 112. Maddox PR, Harrison RE, Mansel LE, LE H. Non-cyclical mastalgia: An improved classification and treatment. *Br J Surg* 1989;76:901-4.
 113. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. *Semin Reprod Med* 2002;20:365-74.
 114. Marshall JK, Griffith KA, Haffty BG, Solin LJ, Vicini FA, McCormick B, et al. Conservative management of Paget disease of the breast with radiotherapy: 10- and 15-year results. *Cancer* 2003;97:2142-9.
 115. Mastro LD, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. *Breast Cancer Res Treat* 1997;43:183-90.
 116. Medscape: Drugs, Diseases, Procedures [Internet]. New York: Medscape; C1994-2012 [cited 2012Jan18] Breast Embryology. available from: <http://emedicine.medscape.com/article/1275146-overview/>.
 117. Messinis IE, Lolis D. Treatment of premenstrual mastalgia with tamoxifen. *Acta Obstet Gynecol Scand* 1988;67:307-9.
 118. Metindir J, Aslan S, Bilir G. Ovarian cyst formation in patients using tamoxifen for breast cancer. *Jpn J Clin Oncol* 2005;35:607-11.
 119. Meunier M, Clough K. Fine needle aspiration cytology versus percutaneous biopsy of nonpalpable breast lesions. *Eur Radiol* 2002;42:10-16.
 120. Montroni I, Santini D, Zucchini G, Fiacchi M, Zanotti S, Ugolini G, et al. Nipple discharge: is its significance as a risk factor for breast cancer fully understood? Observational study including 915 consecutive patients who underwent selective duct excision. *Breast Cancer Res Treat* 2010;123:895-900.
 121. Moon WK, Noh DY, Im JG. Multifocal, mul-ticentric, and contralateral breast cancers: bilateral whole-breast US in the preoperative evaluation of patients. *Radiology* 2002;224:569-76.
 122. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thurlimann B, Paridaens R, Smith I, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. *N Engl J Med* 2009;361:766-76.
 123. Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. *Ann Surg* 2004;240:462-8 discussion 8-71.
 124. NAMS. Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. *Menopause* 2004;11:11-33.
 125. Newman HF, Klein M, Northrup JD, Ray BF, M. D. Nipple discharge. Frequency and pathogenesis in an ambulatory population. *N Y State J Med* 1983;83:928-33.
 126. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Clonal analysis of fibroadenoma and phyllodes tumor of the breast. *Cancer Res* 1993;53:4071-74.
 127. O'Hara MF, Page DL. Adenomas of the breast and ectopic breast under lactational influence. *Hum Pathol* 1985;16:707-12.
 128. Oppong BA, King TA. Recommendations for women with lobular carcinoma in situ (LCIS). *Oncology (Williston Park)* 2011;25:1051-6.
 129. Ortiz-Pagan S, Cunto-Amesty G, Narayan S, Crawford S, Derrick C, Larkin A, et al. Effect of Paget's disease on survival in breast cancer: an exploratory study. *Arch Surg* 2011;146:1267-70.
 130. Padden D. Mastalgia: evaluation and management. *Nurse Pract Forum* 2000;11:213-8.
 131. Page DL, Anderson TJ. Diagnostic histopathology of the breast. Edinburgh, Scotland: Churchill Livingstone; 1987
 132. Page DL, Dupont WD, Rogers LW. Ductal involvement by cells of atypical lobular hyperplasia in the breast: a long-term follow-up study of cancer risk. *Hum Pathol* 1988;19:201-7.
 133. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. *J Clin Oncol* 2006;24 3726-34.
 134. Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. *Ann Intern Med* 2000;132:788-93.
 135. Park MS, Oh KK, Kim EK, SI. L. Multifaces of sonographic

- findings of galactocele: comparison according to its association with pregnancy. *J Korean Radiol Soc* 1993;42:699-703.
136. Parker SH, Burbank F, Jackman RJ, Aucreman CJ, Cardenosa G, Cink TM, et al. Percutaneous large-core breast biopsy: a multi institutional study. *Radiology* 1994;193:359-64.
 137. Parker SH, Jobe WE, Dennis MA, Stavros AT, Johnson KK, Yakes WF, et al. US-guided automated large-core breast biopsy. *Radiology* 1993;187:507-11.
 138. Parker SH. Sonographically Guided Directional Vacuum-Assisted Breast Biopsy Using a Handheld Device. *AJR Am J Roentgenol* 2001;177:405-8.
 139. Pashby NL, Mansel RE, Hughes LE, Hanslip JI, Preece P. A clinical trial of evening primrose oil in mastalgia. *Br J Surg* 1981;68:801-24.
 140. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. *Genet Med* 2010;12:245-59.
 141. Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. *N Engl J Med* 2005;353:1773-83.
 142. Ponzzone R, Biglia N, Jacomuzzi ME, Maggiorotto F, Mariani L, Sismondi P. Vaginal estrogen therapy after breast cancer: Is it safe? *European J Cancer* 2005;41:2673-81.
 143. Porter J. Hormonal regulation of breast development and activity. *J Invest derm* 1974;63:85-92.
 144. Powles TJ, Jones AL, Ashley SE, O'Brien ME, Tidy VA, Treleavan J, et al. The Royan Marson Hospital pilot tamoxifen chemoprevention trial. *Breast Cancer Res Treat* 1994;31:73-82.
 145. Practice. ACOOaGCoG. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. *Obstet Gynecol* 2006;107:1475-8.
 146. Preece PE, Hanslip JI, Gilbert L. Evening primrose oil (Efamol) for mastalgia. In: Horrobin DF, ed. *Clinical uses of essential fatty acids*. Montreal: Eden Press; 1982; 147-54.
 147. Pye JK, Mansel RE, LE H. Clinical experience of drug treatments for mastalgia. *Lancet* 1985;2:373-7.
 148. Ramakrishnan R, Khan SA, Badve S. Morphological changes in breast tissue with menstrual cycle. *Mod Pathol* 2002;15:1348-56.
 149. Rea D, Hasenburg A, Seynaeve C, Jones S, Vannezel J, Paridaens R, et al. Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer. Presented at the 32nd Annual San Antonio Breast Cancer Symposium, Tx, December 9-13, 2009.
 150. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. *Lancet Oncol* 2011;12:1101-8.
 151. Regan MM, Pagani O, Walley B, Torrissi R, Perez EA, Francis P, et al. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? *Ann Oncol* 2008;19:1231-41.
 152. Revesz E, Khan SA. What are safe margins of resection for invasive and in situ breast cancer? *Oncology (Williston Park)* 2011;25:890-5.
 153. Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, et al. Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. *J Clin Oncol* 2011;29:4266-72.
 154. Robbins SL, Cotran RS, Kumar V. *Pathologic Basis of Disease*, 3rd ed. Tokyo: Igaku-Shoin Saunders; 1984. p.1165.
 155. Rosen PP, Caicco JA. Florid papillomatosis of the nipple. A study of 51 patients, including nine with mammary carcinoma. *Am J Surg Pathol* 1986;10:87-101.
 156. Rosen PP. Adenomyoepithelioma of the breast. *Hum Pathol* 1987;18:1232-7.
 157. Rosolowich V, Saettler E, Szuck B, Lea RH, Le vesgue P, weisberg F, et al: Society of Obstetricians and Gynecologists of Canada (SOGC). Mastalgia. *J Obstet Gynaecol Can* 2006;28:49-71.
 158. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288:321-33.
 159. Roy JA SC, Pritchard K. Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? *J Clin Oncol* 1996;14:997-1006.
 160. Sauer G, Deissler H, Strunz K, Helms G, Rimmel E, Koretz K, et al. Ultrasound-guided large core needle biopsies of breast lesions: analysis of 962 cases to determine the number of samples for reliable tumour classification. *Br J Cancer* 2005;92:231-35.
 161. Schoultz VE, LE R. Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. *J Natl Cancer Inst* 2005;97:533-5.
 162. Senkus-Konefka E, Konefka T, Jassem J. The effects of

- tamoxifen on the female genital tract. *Cancer Treat Rev* 2004;30:291-301.
163. Seoud M, El-saghir N, Salem Z, Shamseddine A, Awwad J, Medawar W, et al. Tamoxifen and ovarian cysts: a prospective study. *Eur J Obstet Gynecol* 2001;100:77-80.
164. Sestak I, Sestak J, Sapunar F, Eastell R, Forbes JF, Bianco AR, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. *Lancet* 2008;9:866-72.
165. Shetty MK, Shah YP, Sharman RS. Prospective evaluation of the value of combined mammographic and sonographic assessment in patients with palpable abnormalities of the breast. *J Ultrasound Med* 2003;22:263-8.
166. Shushan A, Peretz T, Mor-Yosef S. Therapeutic approach to ovarian cysts in tamoxifen-treated women with breast cancer. *Int J Gynaecol Obstet* 1996;52:249-53.
167. Sickles EA. Breast imaging: from 1965 to the present. *Radiology* 2000;215:1-16.
168. Simmons R, Adamovich T, Brennan M, Christos P, Schultz M, Eisen C, et al. Nonsurgical evaluation of pathologic nipple discharge. *Ann Surg Oncol* 2003;10:113-6.
169. Sismondi P BN, Volpi E, Giai M, de Grandis T. Tamoxifen and endometrial cancer. *Ann N Y Acad Sci* 1994;734:310-21.
170. Sloane JP, Ellman R, Anderson TJ, Brown CL, Coyne J, Dallimore NS, et al. Consistency of histopathological reporting of breast lesions detected by screening findings of the UK National External Quality Assessment(EQA) Scheme. U.K. National Coordinating Group for Breast Screening Pathology. *Eur J Cancer* 1994;30A:1414-19.
171. Smith DM Jr, Peters TG, Donegan WL, Montgomery's areolar tubercle. A light microscopic study. *Arch Pathol Lab Med* 1982;106:60-3.
172. Smith RL, Pruthi S, LA. F. Evaluation and management of breast pain. *Mayo Clin Proc* 2004;79:353-72.
173. Son BH, Ahn SH, Kim SW, Kang E, Park SK, Lee MH, et al. Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: The Korean Hereditary Breast Cancer (KOHBRA) Study. *Breast Cancer Res Treat* 2012;113(3):1143-52.
174. Son EJ, Oh KK, Kim EK. Pregnancy-associated breast disease: radiologic features and diagnostic dilemmas. *Yonsei Med J* 2006;47:34-42.
175. Srivastava A, Mansel RE, Arvind N, Prasad K, Dhar A, Chabra A. Evidence-based management of Mastalgia: a meta-analysis of randomised trials. *Breast Edinburgh Scotland* 2007;16:503-12.
176. Stavros AT, Thickmann D, Rapp CL, Dennis MA, Parker SH, Sisney GA. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. *Radiology* 1995;196:123-34.
177. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. *JAMA* 2003;289:2827-34.
178. Stomper PC, Connolly JL, Mayer JE, Harris JR. Clinically occult ductal carcinoma in situ detected with mammography: analysis of 100 cases with radiologic-pathologic correlation. *Radiology* 1989;172:235-41.
179. Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. *J Clin Oncol* 1991;9:1283-97.
180. Tamoxifen for early breast cancer. *Cochrane Database Syst Rev* 2001CD000486.
181. Tavassoli FA, MacGrogan G. Central atypical papillomas of the breast: a clinicopathological study of 119 cases. *Virchows Arch* 2003;443:609-17.
182. Tavassoli FA. Myoepithelial lesions of the breast. Myoepitheliosis, adenomyoepithelioma, and myoepithelial carcinoma. *Am J Surg Pathol* 1991;15:554-68.
183. Tavassoli FA, Yeh IT. Lactational and clear cell changes of the breast in nonlactating nonpregnant women. *Am J Clin Pathol* 1987;87:23-9.
184. Terada S, Uchida K, Suzuki N, Akasofu K. A lactating adenoma of the breast. *Gynecol Obstet Invest* 1992;34:126-8.
185. Turner-Warwick R. The lymphatics of the breast. *Br J Surg* 1959;46:574-82.
186. Vargas HI, Vargas MP, Eldrageely K, Gonzalez KD, Burla ML, Venegas R, et al. Outcomes of surgical and sonographic assessment of breast masses in women younger than 30. *Am Surg* 2005;71:716-9.
187. Venta LA. Image-guided biopsy of non-palpable breast lesions. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. *Diseases of the breast*, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000: 149-64.
188. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. *JAMA* 2006;295:2727-41.
189. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. *J Clin Oncol* 2006;24:5769-79.
190. Wikipedia [Internet]. Wikimedia Foundation, Inc; [cited-2011Sep24]. Available from: <http://en.wikipedia.org/>.
191. Wilson MC, Sellwood RA. Therapeutic value of a support-

- ing brassiere in mastodynia. *Br Med J* 1976;2:90.
192. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Pre-operative chemotherapy in patients with operable breast cancer: nineyear results from National Surgical Adjuvant Breast and Bowel Project B-18. *J Natl Cancer Inst Monogr* 2001;30:96-102.
 193. Wong JS, Kaelin CM, Troyan SL, Gadd MA, Gelman R, Lester SC, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. *J Clin Oncol* 2006;24:1031-6.
 194. Youk JH, Kim EK, Kim MJ, Kwak JY, Son EJ. Analysis of false-negative results after US-guided 14-gauge core needle breast biopsy. *Eur Radiol* 2010;20:782-9.
 195. Young RH, Clement PB. Adenomyoepithelioma of the breast. A report of threecases and review of the literature. *Am J Clin Pathol* 1988;89:308-14.